Bipolar Disorder
Bipolar Disorder
Bipolar Disorder
Disorder
Bipolar disorder
Suicide
Some people with bipolar disorder become suicidal. Anyone who is
thinking about committing suicide needs immediate attention,
preferably from a mental health professional or a physician. Any-
one who talks about suicide should be taken seriously. Risk for sui-
cide appears to be higher earlier in the course of the illness. Therefore,
recognizing bipolar disorder early and learning how best to manage it may de-
crease the risk of death by suicide.
Signs and symptoms that may accompany suicidal feelings include:
talking about feeling suicidal or wanting to die
feeling hopeless, that nothing will ever change or get better
feeling helpless, that nothing one does makes any difference
feeling like a burden to family and friends
abusing alcohol or drugs
While some suicide attempts are carefully planned over time, others are im-
pulsive acts that have not been well thought out; thus, the final point in the box
above may be a valuable long-term strategy for people with bipolar disorder. Ei-
ther way, it is important to understand that suicidal feelings and actions are
symptoms of an illness that can be treated.With proper treatment, suicidal feel-
ings can be overcome.
nerability to bipolar disorder, has been extremely difficult. But scientists expect
that the advanced research tools now being used will lead to these discoveries
and to new and better treatments for bipolar disorder.
Brain-imaging studies are helping scientists learn what goes wrong in the
brain to produce bipolar disorder and other mental illnesses.8, 9 New brain-im-
aging techniques allow researchers to take pictures of the living brain at work,
to examine its structure and activity, without the need for surgery or other in-
vasive procedures. These techniques include magnetic resonance imaging
(MRI), positron emission tomography (PET), and functional magnetic reso-
nance imaging (fMRI).There is evidence from imaging studies that the brains
of people with bipolar disorder may differ from the brains of healthy individu-
als. As the differences are more clearly identified and defined through research,
scientists will gain a better understanding of the underlying causes of the illness,
and eventually may be able to predict which types of treatment will work most
effectively.
Medications
Medications for bipolar disorder are prescribed by psychiatristsmedical
doctors (M.D.) with expertise in the diagnosis and treatment of mental disor-
ders. While primary care physicians who do not specialize in psychiatry also
may prescribe these medications, it is recommended that people with bipolar
disorder see a psychiatrist for treatment.
Medications known as mood stabilizers usually are prescribed to help
control bipolar disorder.10 Several different types of mood stabilizers are avail-
able. In general, people with bipolar disorder continue treatment with mood
stabilizers for extended periods of time (years). Other medications are added
when necessary, typically for shorter periods, to treat episodes of mania or de-
pression that break through despite the mood stabilizer.
Lithium, the first mood-stabilizing medication approved by the U.S.
Food and Drug Administration (FDA) for treatment of mania, is often
very effective in controlling mania and preventing the recurrence of both
manic and depressive episodes.
Anticonvulsant medications, such as valproate (Depakote) or carba-
mazepine (Tegretol), also can have mood-stabilizing effects and may be
especially useful for difficult-to-treat bipolar episodes.Valproate was
FDA-approved in 1995 for treatment of mania.
Newer anticonvulsant medications, including lamotrigine (Lamictal),
gabapentin (Neurontin), and topiramate (Topamax), are being studied
to determine how well they work in stabilizing mood cycles.
Anticonvulsant medications may be combined with lithium, or with
each other, for maximum effect.
Children and adolescents with bipolar disorder generally are treated
with lithium, but valproate and carbamazepine also are used. Re-
searchers are evaluating the safety and efficacy of these and other psy-
chotropic medications in children and adolescents. There is some evidence
that valproate may lead to adverse hormone changes in teenage girls and poly-
cystic ovary syndrome in women who began taking the medication before age
20.13 Therefore, young female patients taking valproate should be monitored
carefully by a physician.
Women with bipolar disorder who wish to conceive, or who become
pregnant, face special challenges due to the possible harmful effects of
existing mood stabilizing medications on the developing fetus and the
nursing infant.14 Therefore, the benefits and risks of all available treat-
ment options should be discussed with a clinician skilled in this area.
New treatments with reduced risks during pregnancy and lactation are
under study.
Thyroid Function
People with bipolar disorder often have abnormal thyroid gland function.5
Because too much or too little thyroid hormone alone can lead to mood and
energy changes, it is important that thyroid levels are carefully monitored by a
physician.
People with rapid cycling tend to have co-occurring thyroid problems and
may need to take thyroid pills in addition to their medications for bipolar dis-
order. Also, lithium treatment may cause low thyroid levels in some people, re-
sulting in the need for thyroid supplementation.
Be sure to tell the doctor about all side effects you notice during treatment. He
or she may be able to change the dose or offer a different medication to re-
lieve them.Your medication should not be changed or stopped without the
psychiatrists guidance.
Psychosocial Treatments
As an addition to medication, psychosocial treatmentsincluding certain
forms of psychotherapy (or talk therapy)are helpful in providing support,
education, and guidance to people with bipolar disorder and their families.
Studies have shown that psychosocial interventions can lead to increased mood
stability, fewer hospitalizations, and improved functioning in several areas.12 A
licensed psychologist, social worker, or counselor typically provides these ther-
apies and often works together with the psychiatrist to monitor a patients
progress. The number, frequency, and type of sessions should be based on the
treatment needs of each person.
Psychosocial interventions commonly used for bipolar disorder are cogni-
tive behavioral therapy, psychoeducation, family therapy, and a newer tech-
nique, interpersonal and social rhythm therapy. NIMH researchers are studying
how these interventions compare to one another when added to medication
treatment for bipolar disorder.
Cognitive behavioral therapy helps people with bipolar disorder learn to
change inappropriate or negative thought patterns and behaviors associ-
ated with the illness.
Psychoeducation involves teaching people with bipolar disorder about
the illness and its treatment, and how to recognize signs of relapse so
that early intervention can be sought before a full-blown illness episode
occurs. Psychoeducation also may be helpful for family members.
Family therapy uses strategies to reduce the level of distress within the
family that may either contribute to or result from the ill persons symp-
toms.
Interpersonal and social rhythm therapy helps people with bipolar dis-
order both to improve interpersonal relationships and to regularize their
daily routines. Regular daily routines and sleep schedules may help pro-
tect against manic episodes.
As with medication, it is important to follow the treatment plan for any
psychosocial intervention to achieve the greatest benefit.
Other Treatments
In situations where medication, psychosocial treatment, and the combina-
tion of these interventions prove ineffective, or work too slowly to relieve
severe symptoms such as psychosis or suicidality, electroconvulsive therapy
(ECT) may be considered. ECT may also be considered to treat acute
episodes when medical conditions, including pregnancy, make the use of
medications too risky. ECT is a highly effective treatment for severe de-
pressive, manic, and/or mixed episodes.The possibility of long-lasting
memory problems, although a concern in the past, has been significantly
reduced with modern ECT techniques. However, the potential benefits
and risks of ECT, and of available alternative interventions, should be
carefully reviewed and discussed with individuals considering this treat-
ment and, where appropriate, with family or friends.19
Herbal or natural supplements, such as St. Johns wort (Hypericum perfo-
ratum), have not been well studied, and little is known about their effects
on bipolar disorder. Because the FDA does not regulate their produc-
tion, different brands of these supplements can contain different
amounts of active ingredient. Before trying herbal or natural
supplements, it is important to discuss them with your doc-
tor. There is evidence that St. Johns wort can reduce the ef-
fectiveness of certain medications (see http://www.
nimh.nih.gov/events/stjohnwort.cfm).20 In addition, like
prescription antidepressants, St. Johns wort may cause a
switch into mania in some individuals with bipolar disor-
der, especially if no mood stabilizer is being taken.21
Omega-3 fatty acids found in fish oil are being studied to determine
their usefulness, alone and when added to conventional medications, for
long-term treatment of bipolar disorder.22
How Can Individuals and Families Get Help for Bipolar Disorder?
Anyone with bipolar disorder should be under the care of a psychiatrist
skilled in the diagnosis and treatment of this disease. Other mental health pro-
fessionals, such as psychologists, psychiatric social workers, and psychiatric
nurses, can assist in providing the person and family with additional approaches
to treatment.
Help can be found at:
Universityor medical schoolaffiliated programs
Hospital departments of psychiatry
Private psychiatric offices and clinics
Health maintenance organizations (HMOs)
Offices of family physicians, internists, and pediatricians
Public community mental health centers
References
1 Narrow WE. One-year prevalence of depressive disorders among adults 18 and over in the U.S.:
NIMH ECA prospective data. Population estimates based on U.S. Census estimated residential
population age 18 and over on July 1, 1998. Unpublished.
2 American Psychiatric Association. Diagnostic and Statistical Manual for Mental Disorders, fourth edition
(DSM-IV).Washington, DC: American Psychiatric Press, 1994.
3 Hyman SE, Rudorfer MV. Depressive and bipolar mood disorders. In: Dale DC, Federman DD,
eds. Scientific American; Medicine.Vol. 3. New York: Healtheon/WebMD Corp., 2000; Sect. 13, Sub-
sect. II, p. 1.
4 Goodwin FK, Jamison KR. Manic-depressive illness. New York: Oxford University Press, 1990.
5 Geller B, Luby J. Child and adolescent bipolar disorder: a review of the past 10 years. Journal of the
American Academy of Child and Adolescent Psychiatry, 1997; 36(9): 1168-76.
6 NIMH Genetics Workgroup. Genetics and mental disorders. NIH Publication No. 98-4268.
Rockville, MD: National Institute of Mental Health, 1998.
7 Hyman SE. Introduction to the complex genetics of mental disorders. Biological Psychiatry, 1999;
45(5): 518-21.
8 Soares JC, Mann JJ.The anatomy of mood disordersreview of structural neuroimaging studies.
Biological Psychiatry, 1997; 41(1): 86-106.
9 Soares JC, Mann JJ.The functional neuroanatomy of mood disorders. Journal of Psychiatric Research,
1997; 31(4): 393-432.
10 Sachs GS, Printz DJ, Kahn DA, Carpenter D, Docherty JP.The expert consensus guideline series:
medication treatment of bipolar disorder 2000. Postgraduate Medicine, 2000; Spec No:1-104.
11 Sachs GS,Thase ME. Bipolar disorder therapeutics: maintenance treatment. Biological Psychiatry,
2000; 48(6): 573-81.
12 Huxley NA, Parikh SV, Baldessarini RJ. Effectiveness of psychosocial treatments in bipolar disorder:
state of the evidence. Harvard Review of Psychiatry, 2000; 8(3): 126-40.
13 Vainionpaa LK, Rattya J, Knip M,Tapanainen JS, Pakarinen AJ, Lanning P,Tekay A, Myllyla VV, Iso-
jarvi JI.Valproate-induced hyperandrogenism during pubertal maturation in girls with epilepsy. An-
nals of Neurology, 1999; 45(4): 444-50.
14 Llewellyn A, Stowe ZN, Strader JR Jr.The use of lithium and management of women with bipolar
disorder during pregnancy and lactation. Journal of Clinical Psychiatry, 1998; 59(Suppl 6): 57-64; dis-
cussion 65.
15 Thase ME, Sachs GS. Bipolar depression: pharmacotherapy and related therapeutic strategies. Bio-
logical Psychiatry, 2000; 48(6): 558-72.
16 Suppes T,Webb A, Paul B, Carmody T, Kraemer H, Rush AJ. Clinical outcome in a randomized 1-
year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a
history of mania. American Journal of Psychiatry, 1999; 156(8): 1164-9.
17 Tohen M, Sanger TM, McElroy SL,Tollefson GD, Chengappa KN, Daniel DG, Petty F, Centorrino
F,Wang R, Grundy SL, Greaney MG, Jacobs TG, David SR,Toma V. Olanzapine versus placebo in
the treatment of acute mania. Olanzapine HGEH Study Group. American Journal of Psychiatry,
1999; 156(5): 702-9.
18 Rothschild AJ, Bates KS, Boehringer KL, Syed A. Olanzapine response in psychotic depression.
Journal of Clinical Psychiatry, 1999; 60(2): 116-8.
29 U.S. Department of Health and Human Services. Mental health: a report of the Surgeon General.
Rockville, MD: U.S. Department of Health and Human Services, Substance Abuse and Mental
Health Services Administration, Center for Mental Health Services, National Institutes of Health,
National Institute of Mental Health, 1999.
20 Henney JE. Risk of drug interactions with St. Johns wort. From the Food and Drug Administra-
tion. Journal of the American Medical Association, 2000; 283(13): 1679.
21 Nierenberg AA, Burt T, Matthews J,Weiss AP. Mania associated with St. Johns wort. Biological Psy-
chiatry, 1999; 46(12): 1707-8.
22 Stoll AL, Severus WE, Freeman MP, Rueter S, Zboyan HA, Diamond E, Cress KK, Marangell LB.
Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial.
Archives of General Psychiatry, 1999; 56(5): 407-12.
23 Strakowski SM, DelBello MP.The co-occurrence of bipolar and substance use disorders. Clinical
Psychology Review, 2000; 20(2): 191-206.
24 Mueser KT, Goodman LB,Trumbetta SL, Rosenberg SD, Osher FC,Vidaver R, Auciello P, Foy
DW.Trauma and posttraumatic stress disorder in severe mental illness. Journal of Consulting and Clin-
ical Psychology, 1998; 66(3): 493-9.
25 Strakowski SM, Sax KW, McElroy SL, Keck PE Jr, Hawkins JM,West SA. Course of psychiatric and
substance abuse syndromes co-occurring with bipolar disorder after a first psychiatric hospitaliza-
tion. Journal of Clinical Psychiatry, 1998; 59(9): 465-71.
The New York State Office of Mental Health thanks the National Institute
of Mental Health for providing the information contained in this booklet.
Printed by the New York State Office of Mental health in June 2008.